Protease-activated receptors differentially regulate human platelet activation through a phosphatidic acid-dependent...

Area of Science:

• Biochemistry
• Hematology
• Pharmacology

Background:

• Platelet activation is crucial for controlling pathological conditions like coronary artery disease.
• Thrombin is a potent platelet activator, acting through protease-activated receptors (PAR) 1 and PAR4.
• Current direct thrombin inhibitors cause bleeding side effects, necessitating alternative therapeutic strategies targeting PAR-mediated signaling.

Purpose of the Study:

• To investigate the distinct roles of PAR1 and PAR4 in mediating thrombin's action on human platelets.
• To identify specific intracellular signaling pathways involved in PAR1-mediated platelet activation.

Main Methods:

• Utilized PAR1-activating peptide (PAR1-AP) and PAR4-activating peptide (PAR4-AP) to stimulate human platelets.
• Investigated the involvement of phospholipase D (PLD) and phosphatidic acid (PA) signaling pathways.
• Assessed the effects of inhibiting lipid phosphate phosphatase-1 (LPP-1) with propranolol and PLD with primary alcohols.
• Measured Rap1 activation following receptor stimulation.

Main Results:

• Platelet activation by PAR1-AP requires a PLD-mediated PA signaling pathway.
• Inhibition of LPP-1 or PLD significantly attenuated PAR1-AP-induced platelet activation.
• PAR1-specific PA-mediated effects were not due to differential granule secretion.
• Thrombin- or PAR4-AP-induced platelet activation was insensitive to these inhibitors.
• Inhibitors attenuated Rap1 activation by PAR1-AP but not by thrombin or PAR4-AP.

Conclusions:

• Platelet activation by PAR1 is distinctly regulated by a PLD-mediated PA signaling pathway.
• This PAR1-specific pathway represents a potential therapeutic target for thrombosis, offering an alternative to direct thrombin inhibition.
• Understanding these differences in PAR receptor signaling may advance the treatment of thrombotic disorders.